Pharma giant AstraZeneca (AZN) is transitioning its U.S. listing by delisting American Depositary Shares (ADS) from Nasdaq and directly listing its ordinary shares on the New York Stock Exchange (NYSE) starting Monday, February 2, 2026.
ADS and certain debt securities cease trading on the Nasdaq after market close on January 30, 2026. While the ordinary shares (AZN) and debt securities begin trading on the NYSE on February 2, 2026.
The shift simplifies AstraZeneca's (AZN) structure by replacing two-for-one ADS with direct $0.25 ordinary shares, enabling global investors to trade consistently across exchanges without ADS intermediaries.
At the same time, the pharma company is also investing billions in China and partnering with a Chinese biotech on weight-loss drugs. “These investments span the value chain, from drug discovery and clinical development to manufacturing, and bring Chinese innovation to the world,” the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.